Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors
This real-world study identified greater on-label treatment persistence rates at 24 months in patients with active PsA initiating guselkumab versus SC IL-17Ai, overall and among biologic-naïve and biologic-experienced subgroups.
Authors
- Carmine Rossi (ORCID: https://orcid.org/0000-0001-5801-6927)
- Bruno Émond (ORCID: https://orcid.org/0000-0002-0060-765X)
- Kana Yokoji
- Jessica A. Walsh (ORCID: https://orcid.org/0000-0002-4563-0845)
- Timothy Fitzgerald (ORCID: https://orcid.org/0000-0003-3441-1708)
- Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
- Yuxi Wang (ORCID: https://orcid.org/0000-0002-9897-7316)
- Samuel Schwartzbein
- Soumya D. Chakravarty (ORCID: https://orcid.org/0000-0001-7957-838X)
- Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
- Shikha Singla (ORCID: https://orcid.org/0000-0002-5540-8850)
- Patrick Lefèbvre (ORCID: https://orcid.org/0000-0002-2216-5442)
- Dominic Pilon
- Elizabeth Adamson (ORCID: https://orcid.org/0009-0004-6564-0778)
Institutions
- Johnson & Johnson (United States) (US)
- Medical College of Wisconsin (US)
- University of Utah (US)
- Swedish Medical Center (US)
- Southwestern Medical Center (US)
- Exercise and Survivorship Education Cancer Foundation (US)
- Drexel University (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1007/s12325-025-03416-z
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00